
European Journal of Medicinal Chemistry p. 789 - 797 (1998)
Update date:2022-07-29
Topics:
Dal Piaz, Vittorio
Giovannoni, Maria Paola
Castellana, Carla
Palacios, Jose Maria
Beleta, Jorge
Domenech, Teresa
Segarra, Victor
A novel group of heterocyclic-fused 3(2H)-pyridazinones were synthesized and evaluated as PDE III and PDE IV inhibitors and their affinity for 3H Rolipram high affinity binding site was determined. The obtained data demonstrated that some of the new compounds are endowed with potent and selective PDE IV inhibitory activity and greatly attenuated affinity for the Rolipram high affinity binding site that seems to be responsible for unwanted effects. Theoretical calculations, performed on representative compounds, demonstrated the presence of three hydrogen-bonding acceptor regions, of which one looks quite different with respect to literature compounds. This finding could explain the different pharmacological profile of the title compounds with respect to the analogs reported in the literature.
View MoreContact:+86-0512-88957371
Address:shanghai
Contact:+86-515-88356562
Address:No.2, West Daqing Road, Yancheng, Jiangsu, China
Contact:+86-515-88356562
Address:No.2, West Daqing Road, Yancheng, Jiangsu, China
Hangzhou Sartort Biopharma Co., Ltd
website:http://www.sartort.com
Contact:86-571-87039693
Address:No. 57, Tech Park Road, Hangzhou, Zhejiang, China
Tianjin Tensing Fine Chemical Research Develop Centre
Contact:86-022-23718576,13032267585
Address:2-2-201,13 Guiyuan road,Huayuan Industry district,Tianjin,china
Doi:10.1021/ja00149a011
(1995)Doi:10.1016/j.tetlet.2014.03.004
(2014)Doi:10.1055/s-1994-25545
(1994)Doi:10.1016/j.tet.2014.03.037
(2014)Doi:10.1039/c4cc00857j
(2014)Doi:10.1016/j.molcata.2014.01.005
(2014)